Stockreport

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment [Yahoo! Finance]

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF CAMBRIDGE, Mass. April 9, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatm [Read more]